39151-19-4

Usage

Uses

Used in Pharmaceutical Industry:
3',5'-Dimethoxyacetophenone is used as a starting reagent for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of molecules with potential therapeutic properties.
Used in Chemical Synthesis:
3',5'-Dimethoxyacetophenone is used as a starting reagent in the synthesis of 5,7-dimethoxy-3-methylindazole, a compound with potential applications in the development of new drugs and chemicals.
Used in Synthesis of Chiral Compounds:
3',5'-Dimethoxyacetophenone was used in the synthesis of (R)-(+)-1-(3,5-dimethoxyphenyl)ethyl acetate-ether-180, a chiral compound that may have applications in the pharmaceutical industry, particularly in the development of enantiomerically pure drugs.

Preparation

Obtained by reaction of acetyl chloride with 3,5-dimethoxybenzene.

Upstream product

• 186581-53-3 diazomethane 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 14950-55-1 rac-1-(3,5-dimethoxyphenyl)ethan-1-ol 
• 51863-60-6 3,5-dihydroxyacetophenone 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 7664-93-9 sulfuric acid 
• 97025-16-6 3-(3,5-dimethoxyphenyl)-3-oxopropionic acid ethyl ester 
• 75-36-5 acetyl chloride 
• 151-10-0 1,3-Dimethoxybenzene 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 171290-52-1 1-Ethynyl-3,5-dimethoxy-benzene 
• 104-94-9 4-methoxy-aniline 
• 20469-65-2 1-bromo-3,5-dimethoxybenzene 

Downstream Products

• 51863-60-6 3,5-dihydroxyacetophenone 
• 50841-50-4 (2-bromo-1-(3,5-dimethoxyphenyl)ethanone) 
• 51768-56-0 1,3-dimethoxy-5-ethylbenzene 
• 57860-52-3 [4-(3,5-Dimethoxy-phenyl)-pentyl]-dimethyl-amine 
• 54540-82-8 2-(3,5-Dimethoxyphenyl)-4-(4-fluorphenyl)-butan 
• 57860-50-1 2-(3,5-dimethoxyphenyl)-5-phenylpentane 
• 54540-54-4 2-(3,5-Dimethoxyphenyl)-5-(4-Methylphenyl)Pentane 
• 54540-59-9 2(3,5-Dimethoxyphenyl)-6-(4-Fluorophenyl)Hexane 
• 83816-38-0 Lithium; 2-(3,5-dimethoxy-phenyl)-hexan-2-olate 
• 134804-55-0 2-benzyloxy-3',4,5',6-tetramethoxychalcone 
• 128113-91-7 (1S,1'S)-N-(1'-phenylethyl)-1-(3'',5''-dimethoxyphenyl)ethylamine 
• 128113-79-1 (1R,1'S)-N-(1'-phenylethyl)-1-(3'',5''-dimethoxyphenyl)ethylamine 
• 83816-37-9 Lithium; 2-(3,5-dimethoxy-phenyl)-butan-2-olate 
• 122903-58-6 2-(3,5-Dimethoxyphenyl)-2-butanol 

Relevant academic research and scientific papers

Iron-catalyzed domino decarboxylation-oxidation of α,β-unsaturated carboxylic acids enabled aldehyde C-H methylation

A practical and general iron-catalyzed domino decarboxylation-oxidation of α,β-unsaturated carboxylic acids enabling aldehyde C-H methylation for the synthesis of methyl ketones has been developed. This mild, operationally simple method uses ambient air as the sole oxidant and tolerates sensitive functional groups for the late-stage functionalization of complex natural-product-derived and polyfunctionalized molecules.

A simple synthesis of ketone from carboxylic acid using tosyl chloride as an activator

An effective process for the conversion of carboxylic acid to ketone has been discovered. In this process, carboxylic acid has been activated using p-toluene sulphonyl group. Under the optimized condition, aromatic, aliphatic heteroaromatic carboxylic acids have been proved to be good substrates for this methodology. The byproduct of this reaction can be removed very easily during work up process. Also, one equivalent of organometallic reagent is sufficient to complete this transformation.

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

Iron(III)-Catalyzed Hydration of Unactivated Internal Alkynes in Weak Acidic Medium, under Lewis Acid-Assisted Br?nsted Acid Catalysis

Alkylarylalkynes are converted with full regioselectivity into the corresponding arylketones by formal hydration of the triple bond under weak acidic conditions, at times and temperatures (≤95 °C) comparable to those used for terminal alkynes. The process catalyzed by Fe2(SO4)3nH2O in glacial acetic acid exhibits good functional group compatibility, including that with bulky triple bond substituents, and can be extended to the one-pot transformation of aryltrimethylsilylacetylenes into acetyl derivatives via a desilylation-hydration sequence. The overall reactivity pattern along with proton affinity data indicate that the triple bond is activated by proton transfer rather than by π-interaction with the metal ion. This mechanistic feature, at variance with that of noble metal catalysts, accounts for the total regioselectivity and the insensitivity to steric hindrance exhibited by the Fe2(SO4)3nH2O/AcOH catalytic system. (Figure presented.).

HETEROCYCLIC INHIBITORS OF MCT4

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Generation of Aryl and Heteroaryl Magnesium Reagents in Toluene by Br/Mg or Cl/Mg Exchange

The alkylmagnesium alkoxide sBuMgOR?LiOR (R=2-ethylhexyl), which was prepared as a 1.5 m solution in toluene, undergoes very fast Br/Mg exchange with aryl and heteroaryl bromides, producing aryl and heteroaryl magnesium alkoxides (ArMgOR?LiOR) in toluene. These Grignard reagents react with a broad range of electrophiles, including aldehydes, ketones, allyl bromides, acyl chlorides, epoxides, and aziridines, in good yields. Remarkably, the related reagent sBu2Mg?2 LiOR (R=2-ethylhexyl) undergoes Cl/Mg exchange with various electron-rich aryl chlorides in toluene, producing diorganomagnesium species of type Ar2Mg?2 LiOR, which react well with aldehydes and allyl bromides.

ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing ElectrophilicWarheads

Thieno[3,2-d]pyrimidine as an effective pharmacophore has been extensively studied. However, its 2,6-substituted derivatives are rarely reported. In the present study, eighteen 2,6-substituted thieno[3,2-d]pyrimidine derivatives containing electrophilic warheads were designed based on the first known Fibroblast growth factor receptor-4 (FGFR4) inhibitor Blu9931. Unexpectedly, all of the derivatives exhibited negligible activity against FGFR4. However, most of the target compounds exhibited antiproliferative activities against four human cancer cell lines, including A431, NCI-H1975, Ramos and SNU-16. Compound 12 showed the most potent antiproliferative activities on the above four cell lines with IC50 values of 1.4 μM, 1.2 μM, 0.6 μM, and 2.6 μM, respectively. Additionally, the antiproliferative activity of 12 against MDA-MB-221 proved that 12 had the selectivity towards certain tumor cell lines. Furthermore, preliminary structure-Activity relationship analysis was discussed based on the experimental data.

A facile and practical total synthetic route for ampelopsin F and permethylated ?-viniferin

Stilbene dimers (±)-ampelospin F and permethylated (±)-?-viniferin were synthesized by a practical synthetic route with overall yields of 10% and 27%. This route involves triethylsilane-mediated reduction of the 2,3-diarylbenzofuran, and BBr3-mediated one-pot demethylation and cascade intramolecular cyclization reaction.

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

There is provided a compound having Formula I:(I) wherein: R1 is aryl which is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy, or R1 is aryl which is substituted with a second aryl group or an aryloxy group, wherein the second aryl group or the aryloxy group is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy; R2 is C1-4 alkyl; R3 is selected from hydroxyl and OSO2CH3; R4 and R5 are independently selected from hydrogen, hydroxyl and halogen; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; wherein when R3 is hydroxyl and R4 and R5 are not hydroxyl, the optionally substituted aryl group, second aryl group or aryloxy group of R1 is substituted with one or more hydroxyl groups or C1-4 alkoxy groups, or wherein when R3 is hydroxyl, one of R4 and R5 is hydroxyl, provided that the compound is not N-(1-benzylpiperidin-4-yl)-4-(3,4-dihydroxyphenyl)-N-methyl-1H-imidazole-1-carboxamide hydrobromide. The compound may be used as an inhibitor of fatty acid amide hydrolase.